Effect of the new zinc compound beta-alanyl-L-histidinato zinc on bone metabolism in elderly rats

Pharmacology. 1990;41(6):345-9. doi: 10.1159/000138752.

Abstract

The effect of a new zinc compound beta-alanyl-L-histidinato zinc (AHZ) on bone metabolism was investigated in aged rats (30 weeks old). AHZ (1.0, 2.5 and 7.5 mg/100 g body weight) was orally administered to rats 3 times at 24-hour intervals, and the rats were bled 24 h after the last administration. The administration of AHZ (7.5 mg/100 g) did not cause an appreciable alteration of calcium and inorganic phosphorus concentrations in the serum, and zinc, calcium and deoxyribonucleic acid contents in the femoral diaphysis were significantly increased by the administration of AHZ (7.5 mg/100 g). The bone alkaline phosphatase activity was significantly increased by doses of 1.0-7.5 mg AHZ/100 g. These results suggest that AHZ has a stimulatory effect on bone formation and calcification in aged rats.

MeSH terms

  • Administration, Oral
  • Aging / metabolism*
  • Alkaline Phosphatase / metabolism
  • Animals
  • Anti-Ulcer Agents / administration & dosage
  • Anti-Ulcer Agents / pharmacology*
  • Bone and Bones / drug effects
  • Bone and Bones / enzymology
  • Bone and Bones / metabolism*
  • Calcification, Physiologic / drug effects
  • Carnosine* / analogs & derivatives*
  • DNA / metabolism
  • Dipeptides / administration & dosage
  • Dipeptides / pharmacology*
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Femur / enzymology
  • Male
  • Organometallic Compounds / administration & dosage
  • Organometallic Compounds / pharmacology*
  • Rats
  • Rats, Inbred Strains
  • Zinc Compounds

Substances

  • Anti-Ulcer Agents
  • Dipeptides
  • Organometallic Compounds
  • Zinc Compounds
  • polaprezinc
  • Carnosine
  • DNA
  • Alkaline Phosphatase